JPM | 第九届BFC医疗健康国际商务合作投资研讨会

公司于2026年1月11日前往美国旧金山参加第九届BFC医疗健康国际商务合作投资研讨会。

News Center

公司于2026年1月11日前往美国旧金山参加第九届BFC医疗健康国际商务合作投资研讨会。

Developers are recombining or sharpening established drugs, molecules and mechanisms to create a new generation of neurology therapies.

Neurology is back. A suite of high profile approvals — from Biogen and Eli Lilly’s Alzheimer’s disease drugs to Bristol Myers Squibb’s schizophrenia treatment Cobenfy (xanomeline and trospium chloride) and, most recently, Vertex Pharmaceuticals’ non-opioid pain treatment Journavx (suzetrigine) — has placed the category firmly back onto dealmakers’ radars.

Want more product service? Leave us a message

We will contact you within one working day. Please pay attention to your email.

www.iongentherapeutics.com

en.iongentherapeutics.com

0086-25-58881910

E-mail: liaoyunzhi@iongenpharm.com

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business License